The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Johnson & Johnson Discloses U.S. Probe Related to Arthritis Drugs

Johnson & Johnson Discloses U.S. Probe Related to Arthritis Drugs

May 12, 2017 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters) – Healthcare conglomerate Johnson & Johnson said on Monday the U.S. Department of Justice (DOJ) has opened an investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that bought two of its drugs.

You Might Also Like
  • U.S. Judge Cuts $500 Million Verdict over Johnson & Johnson Hip Implants
  • U.S. Could File Charges in Generic Drug Probe by Year-End
  • Sun Pharma Gets U.S. Subpoena over Generic Drugs Pricing

The U.S. healthcare company said its Janssen Biotech Inc. unit received a civil investigative demand from the DOJ regarding an investigation under the False Claims Act related to its arthritis drugs Remicade (infliximab) and Simponi Aria (golimumab).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The company also revealed in its quarterly filing that the U.S. Attorney’s Office in Massachusetts is seeking documents broadly relating to pharmaceutical co-payment support programs for hepatitis C drug Olysiotm (simeprevir), Simponi and Crohn’s disease drug Stelara (ustekinumab).

That office’s subpoena also seeks documents relating to average manufacturer price and best price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies, Johnson & Johnson said in the filing.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Filed Under: Legal Tagged With: Golimumab, infliximab, Johnson & Johnson, Legal, ustekinumab

You Might Also Like:
  • U.S. Judge Cuts $500 Million Verdict over Johnson & Johnson Hip Implants
  • U.S. Could File Charges in Generic Drug Probe by Year-End
  • Sun Pharma Gets U.S. Subpoena over Generic Drugs Pricing
  • Verdict: Johnson & Johnson to Pay More Than $1 Billion for Defective Hip Implants

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)